Torres Remedies Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 13-12-2024
- Paid Up Capital ₹ 2.00 M
as on 13-12-2024
- Company Age 15 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.50 M
as on 13-12-2024
- Satisfied Charges ₹ 4.00 M
as on 13-12-2024
- Revenue 101.73%
(FY 2022)
- Profit 96.84%
(FY 2022)
- Ebitda 100.60%
(FY 2022)
- Net Worth 37.33%
(FY 2022)
- Total Assets 29.00%
(FY 2022)
About Torres Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹3.50 M. The company has closed loans amounting to ₹4.00 M, as per Ministry of Corporate Affairs (MCA) records.
Anand Padmanabhan and Puthiyapurayil Nithya serve as directors at the Company.
- CIN/LLPIN
U74999TN2009PTC070991
- Company No.
070991
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Mar 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Torres Remedies?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anand Padmanabhan  | Managing Director | 25-Jul-2015 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Puthiyapurayil Nithya | Additional Director | 12-Jun-2020 | Current |
Financial Performance of Torres Remedies.
Torres Remedies Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 101.73% increase. The company also saw a substantial improvement in profitability, with a 96.84% increase in profit. The company's net worth Soared by an impressive increase of 37.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Torres Remedies?
In 2020, Torres Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Dhanlaxmi Bank Limited Creation Date: 28 Oct 2021 | ₹3.50 M | Open |
Others Creation Date: 08 Aug 2018 | ₹1.00 M | Satisfied |
Union Bank Of India Trivandrum Main Branch Creation Date: 23 Jun 2010 | ₹3.00 M | Satisfied |
How Many Employees Work at Torres Remedies?
Unlock and access historical data on people associated with Torres Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Torres Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Torres Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
